AVEO Oncology (AVEO) investors have been promised with new trial readout in August this year. However, while the company has failed multiple times to get approval for tivozanib, other competitors have emerged and brought in new therapy methods for renal cell carcinoma ((RCC)). Besides that, there are multiple issues related to the approval of tivozanib, which makes this company an unattractive buy.
Summary
Tivozanib is the highest developed drug and the only marketed drug of AVEO. It was approved by the EMA in August 2017, but the company has a problem to get